Copyright Reports & Markets. All rights reserved.

Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 PCR
    • 1.4.3 In-situ Hybridization
    • 1.4.4 Immunohistochemistry
    • 1.4.5 Sequencing
    • 1.4.6 Others
  • 1.5 Market by Application
    • 1.5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Application: 2020 VS 2026
    • 1.5.2 Oncology
    • 1.5.3 Neurological Disorders
    • 1.5.4 Cardiovascular Disease
    • 1.5.5 Immunological Disorders
    • 1.5.6 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Perspective (2015-2026)
  • 2.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Growth Trends by Regions
    • 2.2.1 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Market Size
    • 3.1.1 Global Top Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Players by Revenue (2015-2020)
    • 3.1.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio
    • 3.2.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Revenue in 2019
  • 3.3 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players Head office and Area Served
  • 3.4 Key Players Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Product Solution and Service
  • 3.5 Date of Enter into Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Historic Market Size by Type (2015-2020)
  • 4.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)
  • 5.2 Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2020)
  • 6.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players in North America (2019-2020)
  • 6.3 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
  • 6.4 North America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2020)
  • 7.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players in Europe (2019-2020)
  • 7.3 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
  • 7.4 Europe Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)

8 China

  • 8.1 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2020)
  • 8.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players in China (2019-2020)
  • 8.3 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
  • 8.4 China Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2020)
  • 9.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players in Japan (2019-2020)
  • 9.3 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
  • 9.4 Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2020)
  • 10.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)

11 India

  • 11.1 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2020)
  • 11.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players in India (2019-2020)
  • 11.3 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
  • 11.4 India Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size (2015-2020)
  • 12.2 Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type (2015-2020)
  • 12.4 Central & South America Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Qiagen NV
    • 13.1.1 Qiagen NV Company Details
    • 13.1.2 Qiagen NV Business Overview
    • 13.1.3 Qiagen NV Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.1.4 Qiagen NV Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020))
    • 13.1.5 Qiagen NV Recent Development
  • 13.2 GE Healthcare
    • 13.2.1 GE Healthcare Company Details
    • 13.2.2 GE Healthcare Business Overview
    • 13.2.3 GE Healthcare Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.2.4 GE Healthcare Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
    • 13.2.5 GE Healthcare Recent Development
  • 13.3 Agilent Technologies
    • 13.3.1 Agilent Technologies Company Details
    • 13.3.2 Agilent Technologies Business Overview
    • 13.3.3 Agilent Technologies Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.3.4 Agilent Technologies Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
    • 13.3.5 Agilent Technologies Recent Development
  • 13.4 F Hoffman La Roche
    • 13.4.1 F Hoffman La Roche Company Details
    • 13.4.2 F Hoffman La Roche Business Overview
    • 13.4.3 F Hoffman La Roche Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.4.4 F Hoffman La Roche Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
    • 13.4.5 F Hoffman La Roche Recent Development
  • 13.5 Foundation Medicine
    • 13.5.1 Foundation Medicine Company Details
    • 13.5.2 Foundation Medicine Business Overview
    • 13.5.3 Foundation Medicine Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.5.4 Foundation Medicine Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
    • 13.5.5 Foundation Medicine Recent Development
  • 13.6 Thermo Fisher Scientific Inc.
    • 13.6.1 Thermo Fisher Scientific Inc. Company Details
    • 13.6.2 Thermo Fisher Scientific Inc. Business Overview
    • 13.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.6.4 Thermo Fisher Scientific Inc. Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
    • 13.6.5 Thermo Fisher Scientific Inc. Recent Development
  • 13.7 Leica Biosystems Nussloch GmBH
    • 13.7.1 Leica Biosystems Nussloch GmBH Company Details
    • 13.7.2 Leica Biosystems Nussloch GmBH Business Overview
    • 13.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.7.4 Leica Biosystems Nussloch GmBH Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
    • 13.7.5 Leica Biosystems Nussloch GmBH Recent Development
  • 13.8 Pfizer
    • 13.8.1 Pfizer Company Details
    • 13.8.2 Pfizer Business Overview
    • 13.8.3 Pfizer Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Introduction
    • 13.8.4 Pfizer Revenue in Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Business (2015-2020)
    • 13.8.5 Pfizer Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Qiagen NV
    GE Healthcare
    Agilent Technologies
    F Hoffman La Roche
    Foundation Medicine
    Thermo Fisher Scientific Inc.
    Leica Biosystems Nussloch GmBH
    Pfizer

    Market segment by Type, the product can be split into
    PCR
    In-situ Hybridization
    Immunohistochemistry
    Sequencing
    Others
    Market segment by Application, split into
    Oncology
    Neurological Disorders
    Cardiovascular Disease
    Immunological Disorders
    Others

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now